Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
病毒疫苗2
- Development stage
- Preclinical
- Lead developer
- NeoCura
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
病毒疫苗2 (Viral Vaccine 2) is an mRNA-based prophylactic vaccine candidate being developed by Beijing Neocura Bio-Medical Technology (北京新合睿恩生物医疗科技) for the prevention of viral infections. Leveraging Neocura's proprietary AI-enabled RNA drug design platform, the vaccine is designed to express specific viral antigens to trigger robust humoral and cellular immune responses. The candidate is currently in preclinical development.
- Other names
- Viral Vaccine 2virus vaccine 2
Beyond the preview
Go deeper on 病毒疫苗2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 病毒疫苗2.